News

Aligos Therapeutics Set to Present Advancements at The Liver Meeting

Aligos Therapeutics Set to Present Advancements at The Liver Meeting

Exciting Presentations on Aligos Therapeutics' Innovations

Aligos Therapeutics, Inc. (NASDAQ: ALGS), a pioneering clinical-stage biopharmaceutical company, recently announced that four of its abstracts have been accepted for presentation at the prestigious American Association for the Study of Liver Disease’s (AASLD) upcoming The Liver Meeting (TLM) 2024. This event will take place from November 15 to 19, 2024, in San Diego. The significance of this opportunity cannot be underestimated as it allows the company to showcase its advancements in therapies targeting liver and viral diseases.

Abstract Highlights from The Liver Meeting

Among the accepted submissions, one is a late-breaker oral presentation, while three others will be poster presentations. This broad representation of data emphasizes Aligos’s commitment to advancing medical knowledge and improving patient outcomes.

ALG-000184: A Potential Game Changer in Treating Chronic Hepatitis B (CHB)

Understanding chronic hepatitis B is crucial, as it affects millions worldwide. Aligos’s study on ALG-000184 highlights its potential as a first- or best-in-class small molecule designed to facilitate capsid assembly modulation. One notable presentation will focus on monotherapy with ALG-000184, showcasing its effectiveness in achieving high viral suppression rates among untreated HBeAg-positive and HBeAg-negative subjects. This presentation, led by Professor Man-Fung Yuen from the University of Hong Kong, could redefine how chronic hepatitis B is treated.

Details of ALG-000184 Presentation

Abstract #: 1213
Title: Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection
Presenter: Professor Man-Fung Yuen
Date/Time: November 15, 2024, 8:00am – 5:00pm PT

Examining the Effectiveness of ALG-055009

In addition to ALG-000184, Aligos Therapeutics will also present data on ALG-055009, a promising treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The oral presentation on this small molecule thyroid hormone receptor beta (THR-?) agonist will address important findings regarding its tolerability and effectiveness in reducing liver fat in patients. This data is crucial for those searching for new treatment options for MASH, a condition that currently has few effective therapies.

Details of ALG-055009 Presentation

Format: Oral presentation
Title: ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-?) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2
Presenter: Rohit Loomba, MD
Date/Time: November 19, 2024 at 10:30am – 10:40am PT

About Aligos Therapeutics

Founded with the mission of reshaping patient outcomes, Aligos Therapeutics applies a science-driven approach and extensive research and development expertise. Their pipeline specifically targets high unmet medical needs in liver and viral health, particularly focusing on MASH and hepatitis B. This dedication to advancing healthcare through innovative solutions positions Aligos as a leader in biopharmaceutical development.

Investor and Media Relations

For further inquiries about Aligos Therapeutics, you can reach out to Jordyn Tarazi, Vice President of Investor Relations & Corporate Communications, at +1 (650) 910-0427 or via email. Additionally, media inquiries can be directed to Jake Robison, Vice President at Inizio Evoke.

Frequently Asked Questions

What presentations will Aligos Therapeutics deliver at TLM 2024?

Aligos Therapeutics will present four abstracts, including one late-breaker oral presentation focusing on ALG-055009 and three poster presentations highlighting ALG-000184.

What is ALG-000184?

ALG-000184 is a small molecule designed to target capsid assembly modulation for the treatment of chronic hepatitis B, providing significant viral suppression rates.

Who is presenting the information on ALG-000184?

Professor Man-Fung Yuen from the University of Hong Kong will present the findings related to ALG-000184.

What is MASH, and how does ALG-055009 help?

MASH, or Metabolic Dysfunction-Associated Steatohepatitis, is a liver condition. ALG-055009 is a thyroid hormone receptor beta agonist that shows promise in reducing liver fat.

Who can I contact for more information about Aligos Therapeutics?

For investor inquiries, contact Jordyn Tarazi at +1 (650) 910-0427, and for media inquiries, reach out to Jake Robison.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CallRail's New Insight Tool: Navigating the Competitive Landscape

Updated Category News Views 33

How CallRail's New Feature Changes the Game Ever sit in a boardroom meeting and wonder what your lead numbers really mean? CallRail just dropped a new feature that could change that. This AI-powered platform is now decking its 225,000 businesses with market insights to not just know their numbers but to understand how they stack up against their competition in the same...

Continue Reading
Cat Financial Shows Solid Q3 Growth Amid Challenges

Updated Category News Views 82

Healthy Gains in Revenues and Profits Well, Cat Financial's latest report is another piece of the puzzle showing steady, if not spectacular, growth. They've jacked up their revenues by 10% for the third quarter of 2026 compared to last year's same stretch. This puts the revenues at $1.02 billion, a $95 million bump from the previous year. Pretty impressive. The profit saw...

Continue Reading
NeuroSense's Phase 3 Strategies for PrimeC Unveiled

Updated Category News Views 56

How NeuroSense Is Poised to Tackle ALS Treatment Picture this: a room full of people holding their breath, hoping that NeuroSense can deliver the breakthrough they’ve been inching toward. It’s the kind of moment that gives you goosebumps if you've been sloggin' through the biotech trenches. NeuroSense’s pitch at NEALS is more than just a dog and pony show—it's a...

Continue Reading
Why Haunted Attractions Keep Us Coming Back for Fear

Updated Category News Views 0

Welcome to Fear Incarnated Ah, Kansas City. More than just jazz and barbeque. You’ve got these infamous haunted houses that turn every horror flick into a mere Saturday morning cartoon. Enter Edge of Hell and Beast Haunted Attraction. Two horrifying museums of fear that somehow lure us like flies to sugar from miles away. What's the secret sauce? Well, that’s half the...

Continue Reading
Scientology Aids in Huge Meal Effort After Hurricane

Updated Category News Views 19

Weathering the Storm and Feeding the Survivors Alright, so here's the thing—when a hurricane hits, it doesn't just mess up your weekend plans. We're talking about massive upheaval, like making more than 900,000 folks powerless in the Florida Panhandle. No electricity means no cooking, and in comes the disaster crew to save the day. Enter the Churches of Scientology...

Continue Reading
Viedoc and Bioforum Unite: Clinical Data Innovation

Updated Category News Views 19

Revamping Clinical Trials with Data Integration It doesn't take a Wall Street wizard to understand that in today's research game, having data is only half the battle—using it effectively is where the rubber meets the road. Enter Viedoc and Bioforum, two names that are well-acquainted with the grind of the clinical research world. These seasoned pros have joined forces,...

Continue Reading
DayOne's Bold Energy Moves With Sembcorp for Asia Growth

Updated Category News Views 79

It seems the digital world and power supply have locked in a new dance as DayOne Data Centers teams up with Sembcorp Utilities. It's high time we gave this story a solid look, especially with data centers gobbling energy faster than my old trading partner downs an espresso. Tackling Energy Constraints Head-On The digital infrastructure beast is hungry for power, and...

Continue Reading
Bravo Loans Bridge Gaps in Healthcare Real Estate

Updated Category News Views 0

Mezzanine Financing: A Vital Tool for Healthcare Owners Bravo Property Trust is throwing a lifeline to operators in the healthcare sector and beyond with their mezzanine loans aiming right between the eyes of the financing gap. This isn't just some loan for fun. It's a full-on financial tool designed to give some breathing room to folks owning or operating skilled nursing...

Continue Reading
Collective Scoops $100M, Powers Solopreneur's Financial Might

Updated Category News Views 45

Picture This: A Solo Businessman in 2026 Imagine a lone ranger running a show that used to take an entire office. That’s the magic happening with roughly 30 million solo businesses in the U.S. today, and folks, the numbers are staggering. As these one-man-bands push past clunky old systems, a big name is lighting the way: Collective. They raised a hefty $100 million to...

Continue Reading
Tiny Fish Revolutionizes Vertebrate Gene Studies

Updated Category News Views 34

From Small Fish to Big Discoveries: Meet Danionella cerebrum Who would've thought a diminutive fish with a see-through body would give a jolt to the study of vertebrate genomes? Thanks to Danionella cerebrum, researchers at the Whitehead Institute have created the very first complete whole-body single-cell atlas of an adult vertebrate. Forget the Wall Street clamor for a...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Update: Japan's Nikkei 225 Declines and Key Movers

Updated Category News Views 326

Market Overview in Japan The latest market session in Japan closed with stocks trending downward, particularly within the notable Nikkei 225 index, which experienced a decline of 0.77%. This downturn was largely influenced by poor performances in sectors including Paper & Pulp, Rubber, and Transportation Equipment. Sector Performance at Close As trading wrapped up in...

Continue Reading
eIVF Unveils Advanced Embryology Dashboard to Enhance Care

Updated Category News Views 105

eIVF Strengthens Its Commitment to Fertility Innovation eIVF, a leader in electronic medical records (EMR) for the fertility sector, proudly announces significant enhancements to its Fertility Vision platform. This cloud-native tool is designed to revolutionize embryology management by introducing a sophisticated dashboard that provides real-time access to essential...

Continue Reading
Shoals Technologies Group Ventures into Solar Energy in Chile

Updated Category News Views 204

Shoals Technologies Group Ventures into Solar Energy in Chile Shoals Technologies Group, Inc. (Nasdaq: SHLS), a recognized leader in electrical balance of system (EBOS) solutions for the energy transition market, has embarked on an exciting journey into South America with its recent contract for the Alcones Solar Project in Chile. This partnership with CJR Renewables is...

Continue Reading
Kalmar Corporation's Recent Share Buyback Activity Revealed

Updated Category News Views 105

Kalmar Corporation's Share Repurchase Insights Kalmar Corporation has made a significant move by executing a share repurchase, a decision that has grabbed the attention of investors and market analysts alike. This action underscores the company's commitment to enhancing shareholder value and reflects a robust financial strategy. Details of the Share Repurchase On a recent...

Continue Reading
Microsoft's Nadella Confirms Commitment to Stargate Financing

Updated Category News Views 242

Microsoft's Strong Position on Stargate Financing Recently, in a bold assertion, Satya Nadella, the CEO of Microsoft Corporation (NASDAQ: MSFT), addressed the skepticism surrounding the financing of the ambitious Stargate project. This initiative, boasting an estimated budget of $500 billion, is aimed at revolutionizing AI infrastructure and ensuring the United States...

Continue Reading